Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.7 HKD | +0.15% | -2.19% | +0.30% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.30% | 595M | |
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- UBS Adjusts Ocumension Therapeutics’ Price Target to HK$15.90 From HK$23.20, Keeps at Buy